213.37
-2.69 (-1.25%)
| Previous Close | 216.06 |
| Open | 215.25 |
| Volume | 109,565 |
| Avg. Volume (3M) | 1,207,063 |
| Market Cap | 31,501,332,480 |
| Price / Earnings (TTM) | 22.97 |
| Price / Earnings (Forward) | 15.53 |
| Price / Sales | 3.22 |
| Price / Book | 1.71 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2026 |
| Profit Margin | 15.07% |
| Operating Margin (TTM) | 28.05% |
| Diluted EPS (TTM) | 10.12 |
| Quarterly Revenue Growth (YOY) | 6.10% |
| Quarterly Earnings Growth (YOY) | -38.90% |
| Total Debt/Equity (MRQ) | 39.00% |
| Current Ratio (MRQ) | 1.44 |
| Operating Cash Flow (TTM) | 2.58 B |
| Levered Free Cash Flow (TTM) | 3.43 B |
| Return on Assets (TTM) | 5.43% |
| Return on Equity (TTM) | 9.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Mixed | Bullish |
| Drug Manufacturers - General (Global) | Mixed | Bullish | |
| Stock | Biogen Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.33 |
|
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Mid Value |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 92.79% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 May 2026 | CNBC | Biogen advances Alzheimer's drug to late-stage trial despite disappointing data |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |